Harvard‑linked opportunities surfaced on social
Recent social posts flagged Harvard‑connected training and trials, including a Polish Clinical Scholars Research Training Program collaboration noted by @SadejLab and a Mestinon/LDN Life Improvement Trial recruiting near Brigham and Women’s Hospital. Other casual posts signaled current openings or internship vibes within Harvard’s research ecosystem. (x.com) (x.com) (x.com)
Harvard-linked research opportunities are circulating on social media, from a Poland training program run with Harvard Medical School to a Brigham trial testing two off-label drugs. (learn.hms.harvard.edu) (clinicaltrials.gov) One post pointed to the Polish Clinical Scholars Research Training program, which Harvard Medical School says it designed and delivers with Poland’s Medical Research Agency. Harvard says the program will train five cohorts of 100 professionals over five years in clinical research methods, grant writing, and trial leadership. (learn.hms.harvard.edu) (abm.gov.pl) Harvard Medical School says the yearlong certificate includes three in-person workshops, including one in Boston, plus online coursework and a capstone project. The school describes the program as part of a broader Polish government-backed push to expand the country’s clinical trial workforce after the Medical Research Agency was created in 2019. (learn.hms.harvard.edu) Another post highlighted the Life Improvement Trial, a Phase 2 study at Brigham and Women’s Hospital that is testing pyridostigmine, sold as Mestinon, and low-dose naltrexone in people with myalgic encephalomyelitis and chronic fatigue syndrome, also called ME/CFS, and some Long COVID patients. ClinicalTrials.gov lists the study as recruiting, with an estimated enrollment of 160 participants and primary completion in September 2026. (clinicaltrials.gov) Brigham’s public recruitment page says the study is testing the two drugs separately and in combination in a randomized, placebo-controlled, double-blind design. The page lists up to $300 in payment, a three-month participation window, and says public recruitment may be limited because the study is “currently only recruiting patients in the hospital.” (rally.massgeneralbrigham.org) (clinicaltrials.gov) The drugs in the trial are already used for other conditions, not approved by the Food and Drug Administration for ME/CFS. Brigham’s recruitment page says pyridostigmine is approved for myasthenia gravis and naltrexone is used for alcohol or opioid use disorder, while the trial is studying whether lower doses could help fatigue, cognition, and exercise limits in ME/CFS. (rally.massgeneralbrigham.org) The social posts also fit a wider pattern of Harvard-affiliated labs and offices advertising research roles, internships, and student work through scattered online channels rather than one central feed. Harvard’s Student Employment Office says its Faculty Aide Program has introduced “thousands” of students to research, and its April job fair promotes summer and academic-year positions. (seo.harvard.edu) Outside the medical posts, Harvard’s Laboratory for Developmental Studies is advertising a 2026 summer opening in the Spelke Lab for students who can commit 20 to 35 hours a week for at least eight weeks. The lab says interns help recruit families, test children, code data, and present a poster to the Harvard community at summer’s end. (harvardlds.org) Taken together, the posts show how Harvard’s research ecosystem is surfacing in fragments online: a government-backed training pipeline in Poland, a hospital-based drug trial in Boston, and lab openings that move through department pages and personal accounts. (learn.hms.harvard.edu) (rally.massgeneralbrigham.org) (seo.harvard.edu)
